CARL ZEISS MEDITEC AG - BR (AFX.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:AFX - DE0005313704 - Common Stock
41.18 EUR
-0.08 (-0.19%)
Overall AFX gets a fundamental rating of 5 out of 10. We evaluated AFX against 68 industry peers in the Health Care Equipment & Supplies industry. AFX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. AFX has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year AFX was profitable.
AFX had a positive operating cash flow in the past year.
AFX had positive earnings in each of the past 5 years.
Each year in the past 5 years AFX had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.15%, AFX is in the better half of the industry, outperforming 60.29% of the companies in the same industry.
AFX's Return On Equity of 6.67% is in line compared to the rest of the industry. AFX outperforms 51.47% of its industry peers.
With a Return On Invested Capital value of 5.79%, AFX perfoms like the industry average, outperforming 51.47% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for AFX is below the industry average of 9.73%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROIC | 5.79% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
1.3 Margins
AFX's Profit Margin of 6.34% is in line compared to the rest of the industry. AFX outperforms 52.94% of its industry peers.
In the last couple of years the Profit Margin of AFX has declined.
The Operating Margin of AFX (10.03%) is comparable to the rest of the industry.
In the last couple of years the Operating Margin of AFX has declined.
With a Gross Margin value of 52.76%, AFX perfoms like the industry average, outperforming 42.65% of the companies in the same industry.
In the last couple of years the Gross Margin of AFX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% |
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AFX is still creating some value.
Compared to 1 year ago, AFX has about the same amount of shares outstanding.
AFX has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, AFX has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.50 indicates that AFX is not in any danger for bankruptcy at the moment.
AFX's Altman-Z score of 3.50 is fine compared to the rest of the industry. AFX outperforms 67.65% of its industry peers.
AFX has a debt to FCF ratio of 4.41. This is a neutral value as AFX would need 4.41 years to pay back of all of its debts.
With a Debt to FCF ratio value of 4.41, AFX perfoms like the industry average, outperforming 55.88% of the companies in the same industry.
A Debt/Equity ratio of 0.27 indicates that AFX is not too dependend on debt financing.
AFX has a better Debt to Equity ratio (0.27) than 61.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 3.5 |
ROIC/WACC0.86
WACC6.73%
2.3 Liquidity
A Current Ratio of 2.35 indicates that AFX has no problem at all paying its short term obligations.
The Current ratio of AFX (2.35) is better than 69.12% of its industry peers.
AFX has a Quick Ratio of 1.44. This is a normal value and indicates that AFX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of AFX (1.44) is better than 72.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
The earnings per share for AFX have decreased strongly by -19.90% in the last year.
Measured over the past 5 years, AFX shows a small growth in Earnings Per Share. The EPS has been growing by 3.28% on average per year.
AFX shows a small growth in Revenue. In the last year, the Revenue has grown by 7.82%.
Measured over the past years, AFX shows a quite strong growth in Revenue. The Revenue has been growing by 10.78% on average per year.
EPS 1Y (TTM)-19.9%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-14.49%
Revenue 1Y (TTM)7.82%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%8.27%
3.2 Future
The Earnings Per Share is expected to grow by 19.64% on average over the next years. This is quite good.
The Revenue is expected to grow by 6.21% on average over the next years.
EPS Next Y24.48%
EPS Next 2Y22.06%
EPS Next 3Y22.65%
EPS Next 5Y19.64%
Revenue Next Year4.23%
Revenue Next 2Y5.18%
Revenue Next 3Y5.72%
Revenue Next 5Y6.21%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 25.58, which means the current valuation is very expensive for AFX.
Based on the Price/Earnings ratio, AFX is valued a bit cheaper than 64.71% of the companies in the same industry.
AFX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.25.
A Price/Forward Earnings ratio of 20.55 indicates a rather expensive valuation of AFX.
AFX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AFX is cheaper than 61.76% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.98, AFX is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.58 | ||
| Fwd PE | 20.55 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AFX is valued a bit cheaper than 76.47% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AFX is valued a bit cheaper than 64.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.64 | ||
| EV/EBITDA | 12.02 |
4.3 Compensation for Growth
AFX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AFX's earnings are expected to grow with 22.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.04
PEG (5Y)7.8
EPS Next 2Y22.06%
EPS Next 3Y22.65%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.32%, AFX has a reasonable but not impressive dividend return.
AFX's Dividend Yield is a higher than the industry average which is at 1.13.
AFX's Dividend Yield is slightly below the S&P500 average, which is at 1.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.32% |
5.2 History
The dividend of AFX decreases each year by -1.59%.
Dividend Growth(5Y)-1.59%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
AFX pays out 37.19% of its income as dividend. This is a sustainable payout ratio.
DP37.19%
EPS Next 2Y22.06%
EPS Next 3Y22.65%
FRA:AFX (1/12/2026, 7:00:00 PM)
41.18
-0.08 (-0.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners25.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.68B
Revenue(TTM)2.23B
Net Income(TTM)141.22M
Analysts71.82
Price Target51.15 (24.21%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.32% |
Yearly Dividend0.6
Dividend Growth(5Y)-1.59%
DP37.19%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.46%
Min EPS beat(2)-33.88%
Max EPS beat(2)-9.05%
EPS beat(4)1
Avg EPS beat(4)-16.59%
Min EPS beat(4)-36.67%
Max EPS beat(4)13.25%
EPS beat(8)4
Avg EPS beat(8)-3.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.89%
Min Revenue beat(2)-1.14%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-1.14%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.94%
PT rev (3m)-7.71%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.58%
EPS NY rev (3m)-6.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.64%
Revenue NY rev (3m)-0.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.58 | ||
| Fwd PE | 20.55 | ||
| P/S | 1.65 | ||
| P/FCF | 27.64 | ||
| P/OCF | 17.55 | ||
| P/B | 1.74 | ||
| P/tB | 7.61 | ||
| EV/EBITDA | 12.02 |
EPS(TTM)1.61
EY3.91%
EPS(NY)2
Fwd EY4.87%
FCF(TTM)1.49
FCFY3.62%
OCF(TTM)2.35
OCFY5.7%
SpS24.91
BVpS23.66
TBVpS5.41
PEG (NY)1.04
PEG (5Y)7.8
Graham Number29.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROCE | 7.81% | ||
| ROIC | 5.79% | ||
| ROICexc | 5.89% | ||
| ROICexgc | 14.08% | ||
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% | ||
| FCFM | 5.98% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
ROICexc(3y)7.22%
ROICexc(5y)9.75%
ROICexgc(3y)13.97%
ROICexgc(5y)15.82%
ROCE(3y)9.59%
ROCE(5y)13.04%
ROICexgc growth 3Y-8.4%
ROICexgc growth 5Y5.55%
ROICexc growth 3Y-23.03%
ROICexc growth 5Y-5.34%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
F-Score6
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Debt/EBITDA | 1.61 | ||
| Cap/Depr | 60.61% | ||
| Cap/Sales | 3.44% | ||
| Interest Coverage | 10.38 | ||
| Cash Conversion | 60% | ||
| Profit Quality | 94.37% | ||
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 3.5 |
F-Score6
WACC6.73%
ROIC/WACC0.86
Cap/Depr(3y)109.66%
Cap/Depr(5y)110.76%
Cap/Sales(3y)5.42%
Cap/Sales(5y)4.92%
Profit Quality(3y)64.92%
Profit Quality(5y)71.29%
High Growth Momentum
Growth
EPS 1Y (TTM)-19.9%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-14.49%
EPS Next Y24.48%
EPS Next 2Y22.06%
EPS Next 3Y22.65%
EPS Next 5Y19.64%
Revenue 1Y (TTM)7.82%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%8.27%
Revenue Next Year4.23%
Revenue Next 2Y5.18%
Revenue Next 3Y5.72%
Revenue Next 5Y6.21%
EBIT growth 1Y14.86%
EBIT growth 3Y-17.44%
EBIT growth 5Y4.69%
EBIT Next Year66.85%
EBIT Next 3Y28.21%
EBIT Next 5Y26.13%
FCF growth 1Y40.11%
FCF growth 3Y7.85%
FCF growth 5Y-0.04%
OCF growth 1Y-15.15%
OCF growth 3Y3.7%
OCF growth 5Y3.29%
CARL ZEISS MEDITEC AG - BR / AFX.DE FAQ
What is the fundamental rating for AFX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.
What is the valuation status of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?
CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 4 / 10.
What are the PE and PB ratios of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 25.58 and the Price/Book (PB) ratio is 1.74.
Is the dividend of CARL ZEISS MEDITEC AG - BR sustainable?
The dividend rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 3 / 10 and the dividend payout ratio is 37.19%.